Trial reportThe Journal of physiology2012
Effects of acetazolamide on cerebrovascular function and breathing stability at 5050 m.
Trial report in The Journal of physiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 39 citations in OpenAlex.
- Effect of acetazolamide on susceptibility to central sleep apnea in chronic spinal cord injury.Journal of applied physiology (Bethesda, Md. : 1985) · 2020Trial
- Trial
- Cooling down for going up: Could selective 'brain chilling' mitigate high-altitude illness?Experimental physiology · 2025Article
- Loop gain response to increased cerebral blood flow at high altitude.Sleep & breathing = Schlaf & Atmung · 2024Article
- Neuromedin B-Expressing Neurons in the Retrotrapezoid Nucleus Regulate Respiratory Homeostasis and Promote Stable Breathing in Adult Mice.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2023Article
- Hypercapnia-induced vasodilation in the cerebral circulation is reduced in older adults with sleep-disordered breathing.Journal of applied physiology (Bethesda, Md. : 1985) · 2022Article
- Human cerebrovascular function in health and disease: insights from integrative approaches.Journal of physiological anthropology · 2018Review
- Control of Ventilation in Health and Disease.Chest · 2017Review
- Acetazolamide during acute hypoxia improves tissue oxygenation in the human brain.Journal of applied physiology (Bethesda, Md. : 1985) · 2015Article
- Ventilatory oscillations at exercise: effects of hyperoxia, hypercapnia, and acetazolamide.Physiological reports · 2015Article
- AltitudeOmics: Resetting of Cerebrovascular CO2 Reactivity Following Acclimatization to High Altitude.Frontiers in physiology · 2015Article
- Rebuttal from James Duffin and Jason H. Mateika.The Journal of physiology · 2013Article
- Response to letter from Teppema and Berendsen concerning Fan et al. (2012): 'Acetazolamide and cerebrovascular function at high altitude'.The Journal of physiology · 2012Article
- Redox regulation of neurovascular function by acetazolamide: complementary insight into mechanisms underlying high-altitude acclimatisation.The Journal of physiology · 2012Article
- Acetazolamide and cerebrovascular function at high altitude.The Journal of physiology · 2012Article
- Heart rate variability changes at 2400 m altitude predicts acute mountain sickness on further ascent at 3000-4300 m altitudes.Frontiers in physiology · 2012Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
8 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
One of the many actions of the carbonic anhydrase inhibitor, acetazolamide (ACZ), is to accelerate acclimatisation and reduce periodic breathing during sleep. The mechanism(s) by which ACZ may improve breathing stability, especially at high altitude, remain unclear. We tested the hypothesis that acute I.V. ACZ would enhance cerebrovascular reactivity to CO₂ at altitude, and thereby lower ventilatory drive and improve breathing stability during wakefulness. We measured arterial blood gases, minute ventilation (˙VE) and middle cerebral artery blood flow velocity (MCAv) before and 30 min following ACZ administration (I.V. 10 mg kg⁻¹) in 12 healthy participants at sea level and following partial acclimatisation to altitude (5050 m).Measures were made at rest and during changes in end-tidal PCO₂ and PO₂ (isocapnic hypoxia). At sea level, ACZ increased resting MCAv and its reactivity to both hypocapnia and hypercapnia (P < 0.05), and lowered resting VE, arterial O₂ saturation (Sa,O₂ ) and arterial PO₂ (Pa,O₂) (P < 0.05); arterial PCO₂ (Pa,CO₂ ) was unaltered (P > 0.05). At altitude, ACZ also increased resting MCAv and its reactivity to both hypocapnia and hypercapnia (resting MCAv and hypocapnia reactivity to a greater extent than at sea level). Moreover, ACZ at altitude elevated Pa,CO₂ and again lowered resting Pa,O₂ and Sa,O₂ (P <0.05). Although the ˙VE sensitivity to hypercapnia or isocapnic hypoxia was unaltered following ACZ at both sea level and altitude (P > 0.05), breathing stability at altitude was improved (e.g. lower incidence of ventilatory oscillations and variability of tidal volume; P < 0.05). Our data indicate that I.V. ACZ elevates cerebrovascular reactivity and improves breathing stability at altitude, independent of changes in peripheral or central chemoreflex sensitivities. We speculate that Pa,CO₂-mediated elevations in cerebral perfusion and an enhanced cerebrovascular reactivity may partly account for the improved breathing stability following ACZ at high altitude.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.